Corcept Therapeutics Inc’s filing revealed that its Director Swisher Daniel N JR acquired Company’s shares for reported $0.19 million on Oct 10 ’25. In the deal valued at $87.54 per share,2,200 shares were bought.
Then, Guyer William sold 20,000 shares, generating $1,798,782 in total proceeds. Upon selling the shares at $89.94, the Chief Development Officer now owns 5,287 shares.
Before that, Guyer William bought 20,000 shares. Corcept Therapeutics Inc shares valued at $1,797,000 were divested by the Officer at a price of $89.85 per share.
Truist upgraded its Corcept Therapeutics Inc [CORT] rating to a Buy from a a Hold in a research note published on November 06, 2023; the price target was increased to $38 from $29. A number of analysts have revised their coverage, including SVB Securities’s analysts, who began to cover the stock in mid April with a ‘”a Market perform”‘ rating. Piper Sandler began covering CORT with “an Overweight” recommendation on April 04, 2023. Jefferies revised its rating on February 15, 2023. It rated CORT as “a Hold” which previously was an “a Buy”.
Price Performance Review of CORT
On Tuesday, Corcept Therapeutics Inc [NASDAQ:CORT] saw its stock jump 0.82% to $72.12. Over the last five days, the stock has lost -20.15%. Corcept Therapeutics Inc shares have risen nearly 59.38% since the year began. Nevertheless, the stocks have risen 43.12% over the past one year.
How much short interest is there in Corcept Therapeutics Inc?
A steep rise in short interest was recorded in Corcept Therapeutics Inc stocks on 2025-09-30, dropping by -0.24 million shares to a total of 10.64 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 10.88 million shares. There was a decline of -2.22%, which implies that there is a negative sentiment for the stock.
